RiboGene, Inc. is a drug discovery company focused on the identification of novel leads and the development of potential drug candidates for the treatment of infectious diseases. The Company's drug discovery efforts target bacterial, fungal and viral infections for which the efficacy of existing therapies is being threatened by the emergence of drug resistance or for which existing therapies have had limited effectiveness. The Company's drug discovery technology is based on the translational control of gene expression. The Company is using its platform technology to discover compounds that inhibit or interfere with pathogen specific translation. To compliment its drug discovery efforts, the Company also seeks to in-license or acquire compounds with demonstrated activity relevant to certain therapeutic targets. Consistent with this strategy, the Company acquired Emitasol, an intranasal form of metoclopramide.
(Source: 10-K405)
